Lyratzopoulos Georgios, Liu Michael Pang-Hsiang, Abel Gary A, Wardle Jane, Keating Nancy L
Cambridge Centre for Health Services Research, Department of Public Health and Primary Care, Institute of Public Health, Cambridge, United Kingdom. Health Behaviour Research Centre, Department of Epidemiology and Public Health, University College London, Gower Street, London, United Kingdom.
Harvard Medical School, Department of Health Care Policy, Boston, Massachusetts.
Cancer Epidemiol Biomarkers Prev. 2015 Apr;24(4):720-6. doi: 10.1158/1055-9965.EPI-14-0969. Epub 2015 Feb 3.
Fatalistic beliefs may be implicated in longer help-seeking intervals, and consequently, greater risk of advanced stage at cancer diagnosis.
We examined associations between fatalism and stage at diagnosis in a population-based cohort of 4,319 U.S. patients with newly diagnosed lung or colorectal cancer participating in the Cancer Care Outcomes and Research Surveillance (CanCORS) study. Fatalistic beliefs were assessed with an established measure. A fatalism score (range, 4-16) was created by summing Likert scale responses to four items. Cancer stage at diagnosis was abstracted from medical records by trained staff. Logistic regression was used to assess the association between fatalism score and advanced stage at diagnosis (IV vs. I-III), adjusting for sociodemographic and clinical characteristics.
Overall, 917 (21%) patients had stage IV cancers (lung: 28%, colorectal: 16%). The mean fatalism score was 10.7 (median = 11; interquartile range, 9-12). In adjusted analyses, a higher fatalism score was associated with greater odds of stage IV diagnosis (OR per unit increase in fatalism = 1.05; 95% confidence interval 1.02-1.08; P = 0.003). Patients with the highest fatalism score had an adjusted 8.9% higher frequency of stage IV diagnosis compared with patients with the lowest score (25.4% vs. 16.5%).
In this large and socioeconomically, geographically, and ethnically diverse population of patients with lung and colorectal cancer, fatalistic beliefs were associated with higher risk of advanced stage at diagnosis. Longitudinal studies are needed to confirm causation.
These findings support the value of incorporating information about the curability of early-stage cancers in public education campaigns.
宿命论信念可能与更长的求助间隔有关,因此,在癌症诊断时处于晚期的风险更大。
我们在一项基于人群的队列研究中,调查了宿命论与诊断分期之间的关联。该队列包括4319名参与癌症护理结果与研究监测(CanCORS)研究的美国新诊断肺癌或结直肠癌患者。使用一种既定的测量方法评估宿命论信念。通过对四个项目的李克特量表回答求和,得出宿命论得分(范围为4 - 16)。诊断时的癌症分期由经过培训的工作人员从医疗记录中提取。使用逻辑回归评估宿命论得分与诊断时晚期(IV期 vs. I - III期)之间的关联,并对社会人口学和临床特征进行调整。
总体而言,917名(21%)患者患有IV期癌症(肺癌:28%,结直肠癌:16%)。宿命论得分的平均值为10.7(中位数 = 11;四分位间距,9 - 12)。在调整分析中,宿命论得分越高,IV期诊断的几率越高(宿命论得分每增加一个单位,比值比 = 1.05;95%置信区间1.02 - 1.08;P = 0.003)。宿命论得分最高的患者与得分最低的患者相比,IV期诊断的频率经调整后高8.9%(25.4% vs. 16.5%)。
在这个规模庞大、社会经济、地理和种族多样的肺癌和结直肠癌患者群体中,宿命论信念与诊断时处于晚期的较高风险相关。需要进行纵向研究以确认因果关系。
这些发现支持在公众教育活动中纳入有关早期癌症可治愈性信息的价值。